Early-stage non–small cell lung cancer (NSCLC) is treated with stereotactic body radiation therapy (SBRT) Although treatment is generally effective, a small subset of tumors will recur because of radioresistance . Preclinical studies suggested PI3K-AKT-mTOR activation mediates radiotherapy . This study sought to validate this finding in tumor samples from patients who underwent SBRt .